October I

The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.

Currently, 6 separate bills have come out of congressional committees to increase pharmacy benefit managers regulation, with more transparency being the common factor.

The search continues for unique single and combination agents used with anti–PD-1/ PD-L1 approaches.

Although conventional chemotherapy, surgery, and radiotherapy are the foundation of treatment, adverse events such as risk of infection—bacterial and fungal—present clinical challenges.

The classes of cellular immunotherapies and those blocking negative regulatory signals, known as immune checkpoint blockade, have revolutionized cancer treatment.

Richard S. Finn, MD, and R. Kate (Katie) Kelley, MD, emerged in a discussion about the factors that inform treatment decisions for patients with hepatocellular carcinoma during the International Liver Cancer Association Annual Conference 2023.